OCSAW
What one share of Oculis Holding AG holds
Pharmaceutical Preparations
Switzerland, the U.S. and Iceland. We have substantial expertise in therapeutics for the treatment of neuro-ophthalmic and ophthalmic diseases. We are engaged in developing innovative drug candidates that embrace the potential to address significant unmet medical needs.
Oculis Holding AG’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$2.29 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.54 |
| Cash and investments | $1.96 |
| Book value | $4.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$6.15 | $0.01 | −$4.98 | — | −$19.14 |
| 2021 | — | −$6.39 | $0.01 | −$5.46 | — | −$23.99 |
| 2022 | — | −$11.86 | $0.02 | −$8.81 | — | −$31.13 |
| 2023 | — | −$3.31 | $0.00 | −$2.05 | — | $3.73 |
| 2024 | — | −$2.41 | $0.01 | −$1.38 | — | $2.00 |
| 2025 | — | −$2.29 | $0.01 | −$1.54 | — | $4.73 |